INTERNATIONAL MULTIDISCIPLINAR CONFERENCE ON COLORECTAL CANCER

10 March 2015Klaipeda, Lithuania

FIN

AL

PR

OG

RA

MM

E

INTERNATIONAL MULTIDISCIPLINAR

CONFERENCE ON COLORECTAL CANCER

10 March 2015

ORGANIZERS:

LITHUANIAN SOCIETY FOR MEDICAL ONCOLOGY

LITHUANIAN ASSOCIATION OF SURGEONS

LITHUANIAN SOCIETY OF SURGICAL ONCOLOGY

KAUNAS CLUB OF COLOPROCTOLOGIST

KLAIPĖDA UNIVERSITY HOSPITAL

Dear colleagues,

On behalf of the organizers we cordially invite all physicians from the different

fields of medicine to participate in the International Multidisciplinary

Conference Colorectal Cancer.

The conference will focus on the actualities of pathology and molecular

diagnosis of colorectal cancer, the current options for surgery and systemic

therapy, will discuss on the latest science news and clinical implication of

the recent therapies to daily practice, enabling us to offer our patients the most effective treatment.

Yours sincerely,

Lithuanian Society for Medical Oncology, chairperson Dr. Alvydas Cesas

Lithuanian Society of Surgical Oncology, chairperson Prof. Giedrius Barauskas

Lithuanian Association of Surgeons, chairperson Prof. Giedrius Barauskas

Kaunas Club of Coloproctologists, chairperson Prof. Zilvinas Saladzinskas

Klaipėda university hospital, Prof. Vinsas Janušonis

CONFERENCE SECRETARIAT

E-mail: chemoterapija@creativa.lt

Tel: +3706 03 78 930

Address: A. Jaksto str. 14-2, Vilnius, Lithuania

Web: www.creativa.lt

MAIN SPONSOR: SPONSORS:

GOLD SPONSORS:

Venue:

Europa City Hotel Aurora Nemuno str. 51

LT-91190 Klaipeda

Lithuania

INTERNATIONAL MULTIDISCIPLINAR CONFERENCE ON COLORECTAL CANCER

10 March 2015

INTERNATIONAL MULTIDISCIPLINAR

CONFERENCE ON COLORECTAL CANCER

10 March 2015

FINAL PROGRAMME

10:00-10:30 registration

10:30-13:45 Session I: Conservative And Surgical Management Of Colorectal Cancer?

10:30-10:45 Colorectal cancer surgery in Lithuania.Ž. Saladžinskas (LSMUL), E.Poškus (VUSL), N. Samalavičius (NVI)

10:45-11:00 Colorectal cancer surgery in Slovak Republic.J. Korček (Nitra, Slovak Republic)

11:00-11:30 Modulating functional liver reserve in post-chemotherapy patient.E. Jonas, (Stocholm, Sweden)

11:30-11:45 Imaging in rectal cancer and its value for the assessment of response. I. Gineikienė (LSMU, Kaunas)

11:45-12:00 Adjuvant treatment of rectal cancer. Past and future.R. Jančiauskienė, ( LSMU Kaunas)

Coffee break 12:00-12:30

12:30-12:45 Adjuvant chemotherapy CRC. Are gene signatures ready for use in the selection of patients for adjuvant treatment? E. Baltruškevičienė ( NVI Vilnius)

12:45-13:00 Which neoadjuvant chemoradiotherapy regimen in rectal cancer? Results of RCT. L. Kairevičė , T. Latkauskas, (LSMU, Kaunas)

13:00-13:15 Surgical strategy after complete response neoadjuvant chemoradiotherapy for rectal cancer. P. Žeromskas, A.Tamošiūnas (KUL, Klaipeda)

13:15-13:45 Robotic surgery for rectal cancer G.Virakas (Bochum, Germany)

13:45-14:45 Lunch

14:45-16:30 Session II: Metastatic Colorectal Cancer.

14:45-15:15 Categorization of liver limited mCRC and its approaches – neoadjuvant, conversion, palliative. T. Gruenberger (Vienna, Austria)

15:15-15:30 Behind the scenes: Unusual gut tumors U. Mickys (National Centre of Pathology, VU Santariskiu Clinics Affiliate, Vilnius)

15:30-15:45 Cytoreductive surgery and HIPEC for metastatic colorectal cancer. K. Strupas (VU SK, Vilnius), A. Šlepavičius (KUL, Klaipeda).

15:45-16:00 Multidisciplinary management of peritoneal carcinomatosis due metastatic colorectal cancer: Medical oncology view. A. Česas ( KUL, Klaipeda)

16:00-16:15 Techniques and results of local ablation of metastatic liver tumors . B. Gloor (Bern, Switzerland)

16:15-16:30 Extrahepatic – extrapulmonary CRC metastases: palliation or surgery with intention to treat? G. Barauskas (LSMU, Kaunas)

Coffe break: 16:30-17:00

Plenary session: 17:00-19:35

17:00-17:30 The right drug for the right patient: Phenotype or genotype? T. Gruenberger (Vienna, Austria)

17:30-18:00 Importance of testing molecular markers (KRAS, NRAS, BRAF) in selecting therapies for met-astatic colorectal cancer. M. Geissler (Esslingen, Germany)

18:00-18:30 1st line treatment in mCRC. What is the standard?P. Wysocki (Szczecin, Poland)

18:30-18:45 Case report. – medical oncology. V. Šimonytė-Verbickienė, R. Jančiauskienė (LSMU, Kaunas)

18:45-19:00 Case report – SurgeryT. Latkauskas ( LSMU, Kaunas)

19:00-19:15 Case report – medical oncology N. Lachej (Vilnius, NVI)

19:15-19:35 Q & A

Closing remarks: 19:35

INTERNATIONAL MULTIDISCIPLINAR CONFERENCE ON COLORECTAL CANCER

10 March 2015

INTERNATIONAL MULTIDISCIPLINAR

CONFERENCE ON COLORECTAL CANCER

10 March 2015

Prof. Beat. Gloor (Bern, Switzerland)

Prof. Beat Gloor is a Prof. of Surgery at the Inselspital, the university

hospital at the university of Bern, Switzerland. He studied and trained

in Zürich and Luzern. He also worked in the research team of Howard

Reber, MD and Joe Hines MD at UC Los Angeles.

His main interest is surgical oncology with a special focus on pancreatic

diseases. The Department of gastrointestinal surgery in Bern runs

a research program on computer aided and image-guided surgery

together with the ARTORG Center for Biomedical Engineering

Research of the University Bern aiming at a more precise detection

and/or destruction of liver metastases and also pancreatic tumors.

He also serves as an associate editor for the Journal Digestive Surgery

and editorial board member for the journal Patient Safety in Surgery

Prof. Thomas Gruenberger (Vienna, Austria)

Medical University of Vienna, Austria

Prof. Dr. Thomas Gruenberger is the Head of the 1st Department of

Surgery at the Rudolfstiftung Hospital in Vienna, which is affiliated to

the Medical University of Vienna.

He received his medical degree from the Medical University of Vienna,

Austria. He completed his residency in general surgery at Vienna

General Hospital, Austria, and at the regional hospital in Baden, Lower

Austria. He has also completed his fellowship in surgical Oncology with

specialization in HBP surgery at St. George Hospital, Kogarah, Sydney,

Australia.

He was the Senior Lecturer in Surgery, the Deputy Chief of the liver

unit, and a Research Fellow in the Department of Surgery at the St.

George Hospital - University of New South Wales, Australia. He was a

Consultant in the Department of Surgery at the Medical University of

Vienna, Austria.

His research interest focuses on the following: multi−disciplinary

management of liver metastasis of colorectal cancer as well

as bile duct and gallbladder cancer, liver transplantation, and

lymphangiogenesis.

He is a Board Member of the European Society of Surgical Oncology

(ESSO) and is a member of the: ASCO, ESMO, ESGE, EORTC, OeGHO,

IHPBA, German Society for Surgery, International Liver Transplantation

Society (ILTS), The Transplantation Society of Australia and New

Zealand (TSANZ), Austrian Society for Gastroenterology and

Hepatology and the European Hepato-Pancreato-Biliary Association

(EHPBA).

He has published a significant number of scientific papers and articles

on the following: liver neoplasms, colorectal neoplasms, hepatectomy,

neoadjuvant therapy, local recurrences, and antineoplastic combined

chemotherapy protocols. He is an Editorial Advisory Board member of

the European Journal of Surgical Oncology and the Annals of Surgical

Oncology.

He is a principal investigator for the observational study of pre-

operative von willebrand factor to predict post-operative liver

dysfunction and morbidity after liver resection, and an investigator

for the observational study on the involvement of platelets and

platelet derived growth factors in postoperative liver regeneration,

liver dysfunction and morbidity in patients undergoing hepatectomy.

He is principal investigator and national coordinator of the EORTC

BOS-2 trial, which investigates FOLFOX, FOLFOX+Bevacizumab and

FOLFOX+Panitumumabin the periOP setting of mCRC. 

Prof. Dr. Gruenberger has received the annual scientific award from

Austrian Society for Surgical Oncology (ASSO) (2008) and the annual

scientific award of the Austrian Society of Surgery 2013 and 2014

(Billroth Preis).

Prof. Eduard Jonas (Stocholm, Sweden)

Eduard Jonas MB, ChB (Pret), MMed (Stell), FCS (SA),

PhD (Karolinska Institutet)

Department of Upper Abdominal Surgery, Karolinska University

Hospital and Karolinska Institutet, Stockholm, Sweden

Email: eduard.jonas@ki.se

Eduard Jonas underwent his pre-graduate training at the University of

Pretoria, South Africa obtaining a MBChB in 1985 with distinction in

surgery. He did his surgical training at the University of Stellenbosch

and becoming a Fellow of the South African College of Surgeons in

1995. He served as consultant surgeon in the Upper Gastrointestinal

Service of the Department of General Surgery at Tygerberg hospital

before taking up an endoscopy fellowship position at Karolinska

University Hospital, Stocholm, Sweden in 1997. He obtained a PhD

from the Karolinska Institute in 2002 with a thesis on Imaging-based

Dynamic Liver Testing. He is affiliated to the Karolinska Institute as

associate professor and has held several clinical positions in Karolinska

Institute affiliated hospitals, including Head of Endoscopy at Danderyd

Hospital and is currently appointed as senior consultant in the Hepato-

biliary service of Karolinska University Hospital. His major clinical

interests include hepatobiliary and minimally invasive surgery as

well as interventional gastro-intestinal endoscopy. His research is

focussed on functional hepatobiliary MRI, liver tumour diagnostics and

computer-assisted intervention.

Jozef Korček (Nitra, Slovak Republic)

M.D.PhD.Assoc. Prof. Faculty Hospital Nitra, Slovak Republic- from the year 1979

Academic career Year Institution Scientific field

Acquiring of the present title

2008Trnaviensis Univ.-Trnava

Surgery

Phd 2001Univ. of P.J.Safarik- Košice

Surgery

Msc      

Subspecialty 1987Univ.Hosp.Bulovka- Prague

Coloproctology

Specialty 1988 J.A.Comenius Univ. Surgery II.degree

University (med. school) 1979 J.A.Comenius Univ.  

Representative references in last 10 years (up to 5 references)

1. Diagnostics and therapy of anal incontinence, Environment 2008,168 pp. ISBN – 978 - 80 – 969120 – 7 - 0

2. Combined parasacral vaginal and endorectal approach in surgical treatmen of giant rectocele (case report) Acta Chir Iug , 2006, 2, p. 43 - 49

3. Prniciples of Surgery - Texbook, 2013, 650 pp.

4. Acute intestinal ischaemia, Rozhl.chir. 86, 207, 4, 184 - 187

5. Longo stapled mucosectomyy and Prolapsectomy-Myths and facts ,

Proctologia NRI, 2008, 74

Number of citations 45

Total amount of publications on SCI (or SSCI) list 55

Present participation in scientific projects:

- National (number) 2

- International (number) 2

Additional education (up to 150 words): Interstim therapy, PTQ implants, ABS aplications, Colon and rectum surgery,

Anal stapling, EMG ,Expert of the SSI, Specialisation in Proctology

Prof. Piotr Wysocki (Szczecin, Poland)

Medical Oncologist. Deputy Director of West Pomeranian Cancer

Center, Szczecin, Poland. President-elect of Polish Society of Clinical

Oncology (2015-2019). Graduated from University of Medical Sciences

in Poznan, Poland. Scholarships received: Scholarship from the

Ministry of Health 2000; Scholarship for Young Scientists founded

by “POLITYKA” journal 2001; Scholarships of Fundation for Polish

Science – 2002, 2003; Scholarship of American Society for Clinical

Oncology – IDEA award. Prizes received: Nature Immunology Prize

2000, Polish Prime Minister Prize for outstanding PhD thesis 2002.

Scientific and clinical training – Dept. of Molecular Biology, Roswell

Park Cancer Institute Bufallo, NY (1997) and Dept. of Oncology,

Princess Margaret Hospital in Toronto, Canada (2008). Current leader

of Scientific Committee and member of Clinical Initiative Committee of

Polish Society of Clinical Oncology. Areas of particular clinical interest:

treatment of young cancer patients and patients with metabolic

disorders. Areas of scientific interest – development of novel

immunotherapeutic strategies for treatment of renal-cell, prostate

and breast cancer; definition and targeting of chemoresistance

mechanisms associated with cancer cell stemness and intracellular

metabolic pathways.